9 Jan 2015
Ergomed to Present at the Proactive Investors One2One Investor Forum on 15th January 2015

Guildford, UK – 9th January 2015: Ergomed plc, (LSE: ERGO) a profitable UK-based company, dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, announced that Neil Clark, Chief Financial Officer, is scheduled to present at the Proactive Investors One2One Investor Forum on Thursday, 15th January 2015, in London.

The event will run from 6:00pm to 8:00pm, followed by a drinks reception until approximately 9:00pm.

The Forum will be held at the Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair, W1J 5EB in the Charles Suite (on the 1st Floor).

The event is open to private investors, private client brokers, fund managers, financial institutions, hedge funds, buy & sell side analysts and journalists.

Further information (including a link to register participation) can be found at: http://www.proactiveinvestors.co.uk/register/event_details/263

For further information, please contact:

Hume Brophy
Mary Clark, Supriya Mathur and Hollie Vile
Tel: + 44 203 440 5654
ergomed@humebrophy.com

Oriel Securities
Advisers/Broker to the Company

Jonathan Senior
Tel: +44 207 710 7600

About Ergomed

Ergomed Plc is a profitable UK-based company, providing drug development services to the pharmaceutical industry and has a growing portfolio of co-development partnerships. It operates in over 40 countries.

Ergomed provides clinical development, trial management and pharmacovigilance services to over 60 clients ranging from top 10 pharmaceutical companies to small and mid-sized drug development companies. Ergomed successfully manages clinical development from Phase I through to late phase programmes.

Ergomed has a wide therapeutic focus, with a particular expertise in oncology, neurology and immunology and the development of orphan drugs. Ergomed believes its approach to clinical trials is differentiated from that of other providers by its innovative Study Site Management model and the use of Study Physician Teams, resulting in a close relationship between Ergomed and the physicians involved in clinical trials.

As well as providing high quality clinical development services, Ergomed is building a portfolio of co-development partnerships with pharma and biotech companies which share the risks and rewards of drug development. Ergomed leverages its expertise and services in return for carried interest in the drugs under development. For further information, visit: https://www.ergomedplc.com